체외진단약 관련 최근(2016-2024년) 제휴와 라이선스 계약의 동향에 대해 분석하고, 전체적인 거래 건수의 추이 및 재무면(지불 조건) 동향, 주요 기업(총 25사)에 의한 거래 성립 동향, 계약 조건 동향, 기술별 상세 동향 등을 조사했으며, 최근 주요 제휴 거래의 상세 정보를 정리하여 전해드립니다.
목차
주요 요약
제1장 서론
제2장 체외진단약 관련 거래 성립 동향
- 서론
- 체외진단약 관련 거래 장기적 동향
- 체외진단약 관련 가장 활발한 거래업체
- 체외진단약 관련 거래 : 거래 유형별
- 체외진단약 관련 거래 : 치료 영역별
- 체외진단약 관련 거래 : 업계별
- 체외진단약 관련 거래 : 거래조건
- 체외진단약 관련 거래 : 거래 총액
- 체외진단약 관련 거래 : 선불금
- 체외진단약 관련 거래 : 마일스톤 지불
- 체외진단약 관련 거래 : 로열티율
제3장 체외진단약 관련 주요 거래
제4장 체외진단약 관련 가장 활발한 거래 기업
- 서론
- 가장 활발한 체외진단약 관련 거래 기업
- 가장 활발한 체외진단약 관련 기업 개요
제5장 체외진단약 관련 계약 체결 디렉토리
제6장 체외진단약 관련 거래 : 기술 종류별
- 거래 리스트
- 거래 리스트 : 체외진단약 관련, 기업별(ABC순)
- 거래 리스트 : 체외진단약 관련, 거래 유형별
- 거래 리스트 : 체외진단약 관련, 치료 영역별
- 거래 유형의 정의
- Biopharma Research Ltd 소개
- 현재의 제휴
- 현재의 계약
- Current Partnering 간행 최근 리포트의 타이틀
KSA
In Vitro Diagnostic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the in vitro diagnostic deals entered into by the worlds leading biopharma companies.
Fully revised and updated, the report provides details of in vitro diagnostic deals from 2016 to 2024.
The report provides a detailed understanding and analysis of how and why companies enter in vitro diagnostic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
The report includes collaboration, development, research and licensing deals.
This report contains a comprehensive listing of 267 in vitro diagnostic deals announced since 2016 including financial terms where available including links to online deal records of actual in vitro diagnostic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of in vitro diagnostic dealmaking.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in in vitro diagnostic dealmaking since 2016.
Chapter 3 provides an overview of the leading in vitro diagnostic deals since 2016. Deals are listed by headline value.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in in vitro diagnostic dealmaking with a brief summary followed by a comprehensive listing of in vitro diagnostic deals, as well as contract documents available in the public domain.
Chapter 5 provides a comprehensive and detailed review of in vitro diagnostic deals signed and announced since Jan 2016, where a contract document is available in the public domain.
Chapter 6 provides a comprehensive and detailed review of in vitro diagnostic partnering deals signed and announced since Jan 2016. The chapter is organized by specific in vitro diagnostic technology type in focus.
The report also includes numerous table and figures that illustrate the trends and activities in in vitro diagnostic deal making since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Key benefits
In Vitro Diagnostic Collaboration and Licensing Deals provides the reader with the following key benefits:
- Understand deal trends since 2016
- Browse in vitro diagnostic collaboration and licensing deals
- Benchmark analysis - identify market value of transactions
- Financials terms - upfront, milestone, royalties
- Directory of deals by company A-Z, deal type and therapy area
- Leading deals by value
- Most active dealmakers
- Identify assets and deal terms for each transaction
- Access contract documents - insights into deal structures
- Due diligence - assess suitability of your proposed deal terms for partner companies
- Save hundreds of hours of research time
Report scope
- In Vitro Diagnostic Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of in vitro diagnostic trends and structure of deals entered into by leading biopharma companies worldwide.
In Vitro Diagnostic Collaboration and Licensing Deals includes:
- Trends in in vitro diagnostic dealmaking in the biopharma industry
- Directory of in vitro diagnostic deal records covering pharmaceutical and biotechnology
- The leading in vitro diagnostic deals by value
- Most active in vitro diagnostic licensing dealmakers
- In Vitro Diagnostic Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.
Analyzing contract agreements allows due diligence of:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Table of Contents
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in in vitro diagnostic dealmaking
- 2.1. Introduction
- 2.2. In vitro diagnostic deals over the years
- 2.3. Most active in vitro diagnostic dealmakers
- 2.4. In vitro diagnostic deals by deal type
- 2.5. In vitro diagnostic deals by therapy area
- 2.6. In vitro diagnostic deals by industry sector
- 2.7. Deal terms for in vitro diagnostic deals
- 2.7.1 In vitro diagnostic deals headline values
- 2.7.2 In vitro diagnostic deal upfront payments
- 2.7.3 In vitro diagnostic deal milestone payments
- 2.7.4 In vitro diagnostic royalty rates
Chapter 3 - Leading in vitro diagnostic deals
- 3.1. Introduction
- 3.2. Top in vitro diagnostic deals by value
Chapter 4 - Most active in vitro diagnostic dealmakers
- 4.1. Introduction
- 4.2. Most active in vitro diagnostic dealmakers
- 4.3. Most active in vitro diagnostic deals company profiles
Chapter 5 - In vitro diagnostic contracts dealmaking directory
- 5.1. Introduction
- 5.2. In vitro diagnostic contracts dealmaking directory
Chapter 6 - In vitro diagnostic dealmaking by technology type
- Deal directory
- Deal directory - In vitro diagnostic deals by company A-Z
- Deal directory - In vitro diagnostic deals by deal type
- Deal directory - In vitro diagnostic deals by therapy area
- Deal type definitions
- About Biopharma Research Ltd
- Current Partnering
- Current Agreements
- Recent report titles from Current Partnering
Table of figures
- Figure 1: In vitro diagnostic deals since 2016
- Figure 2: Active in vitro diagnostic dealmaking activity - 2016 - 2024
- Figure 3: In vitro diagnostic deals by deal type since 2016
- Figure 4: In vitro diagnostic deals by therapy area since 2016
- Figure 5: In vitro diagnostic deals by industry sector since 2016
- Figure 6: In vitro diagnostic deals with a headline value
- Figure 7: In vitro diagnostic deals with an upfront value
- Figure 8: In vitro diagnostic deals with a milestone value
- Figure 9: In vitro diagnostic deals with a royalty rate value
- Figure 10: Top in vitro diagnostic deals by value since 2016
- Figure 11: Most active in vitro diagnostic dealmakers 2016 - 2024
- Figure 12: In vitro diagnostic deals by technology type since 2016
